» Articles » PMID: 24293180

Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: a Study of Monographs and Published Literature

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 2013 Dec 3
PMID 24293180
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Over three-quarters of the older population take medications that can potentially cause dry mouth. Physicians or pharmacists rarely inform patients about this adverse effect and its potentially severe damage to the teeth, mouth and general health.

Objectives: The objectives of this study were to (1) identify warnings in the literature about dry mouth associated with the most frequently prescribed pharmaceutical products in Canada; and (2) consider how this information might be obtained by physicians, pharmacists and patients.

Methods: Monographs on the 72 most frequently prescribed medications during 2010 were retrieved from the Compendium of Pharmaceuticals and Specialties (CPS, a standard drug information reference for physicians and pharmacists), the National Library of Medicine's 'DailyMed' database, directly from the manufacturers, and from a systematic search of biomedical journals.

Results: The CPS provided monographs for 43% of the medications, and requests to manufacturers produced the remaining monographs. Mentions of dry mouth were identified in 61% of the products (43% amongst CPS monographs; an additional 43% amongst manufacturers' monographs; 7% in the DailyMed database and 7% from biomedical journals); five medications had contradictory reports in different monographs.

Conclusion: Nearly two-thirds (61%) of the most commonly prescribed medications can cause dry mouth, yet warnings about this adverse effect and its potentially serious consequences are not readily available to physicians, pharmacists, dentists or patients.

Citing Articles

Considering Sex and Gender in Therapeutics throughout the Product Life Cycle: A Narrative Review and Case Study of Gilteritinib.

Maximos M, Brabete A, Le M, Greaves L Can J Hosp Pharm. 2023; 76(3):239-245.

PMID: 37409151 PMC: 10284287. DOI: 10.4212/cjhp.3299.


Potentially Inappropriate Prescribing of Oral Solid Medications in Elderly Dysphagic Patients.

Sestili M, Logrippo S, Cespi M, Bonacucina G, Ferrara L, Busco S Pharmaceutics. 2018; 10(4).

PMID: 30558366 PMC: 6321461. DOI: 10.3390/pharmaceutics10040280.


A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.

Wolff A, Kumar Joshi R, Ekstrom J, Aframian D, Pedersen A, Proctor G Drugs R D. 2016; 17(1):1-28.

PMID: 27853957 PMC: 5318321. DOI: 10.1007/s40268-016-0153-9.

References
1.
Conley R, Kelly D, Nelson M, Richardson C, Feldman S, Benham R . Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005; 28(4):163-8. DOI: 10.1097/01.wnf.0000172993.89879.0f. View

2.
Aubin H . Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002; 62 Suppl 2:45-52. DOI: 10.2165/00003495-200262002-00005. View

3.
Barr R, Bourbeau J, Camargo C, Ram F . Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006; 61(10):854-62. PMC: 2104759. DOI: 10.1136/thx.2006.063271. View

4.
Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T . A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 59(9):829-35. DOI: 10.1016/j.biopsych.2005.09.011. View

5.
Nederfors T, Dahlof C . Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population. Eur J Oral Sci. 1996; 104(3):262-8. DOI: 10.1111/j.1600-0722.1996.tb00076.x. View